Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy. This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy

Evaxion announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.

Evaxion and Pantherna announced that the tumor neoantigens, identified by Evaxion's PIONEER, demonstrates strong immune response.

On January 3, 2023, Evaxion announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

On January 19, 2023, our CEO, Per Norlén, presented the company at RedEye Fight Cancer on January 19, 2023. In the video, you can hear more about how we use the power of our AI to make a unique and personalized treatment for each patient

On December 12, 2022, Evaxion announced that the Company has signed a Vaccine Discovery Collaboration Agreement with ExpreS²ion Biotech Holding AB’s affiliate ExpreS²ion Biotechnologies ApS (“ExpreS2ion") for the joint development of a novel cytomegalovirus (CMV) vaccine candidate.